

### PERSONAL INFORMATION **Thomas Sudhop**

#### WORK EXPERIENCE

---

- June 1992-December 1993 **Medical Doctor / Physician**  
Rheinische Friedrich-Wilhelms Universität Bonn - Medizinische Klinik und Poliklinik (Germany)  
Doctor in internship in Internal Medicine
- January 1994-August 1994 **Medical Doctor / Physician**  
Rheinische Friedrich-Wilhelms Universität Bonn - Medizinische Klinik und Poliklinik (Germany)  
Further special training Internal Medicine / Internship
- September 1994-December 1999 **Medical Doctor / Physician**  
Rheinische Friedrich-Wilhelms Universität Bonn - Institute for Clinical Pharmacology (Germany)  
Specialist training in Clinical Pharmacology / Internship
- January 2000-November 2004 **Senior physician**  
Rheinische Friedrich-Wilhelms Universität Bonn - Institute for Clinical Pharmacology (Germany)  
Senior physician  
Since 2003 Deputy Head
- December 2004-June 2005 **Head of the Clinical Trials Department**  
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (Germany)  
Authorisation of clinical trials on medicinal products including GCP inspections
- July 2005-May 2020 **Head of the Division "Scientific Services"**  
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (Germany)  
Division includes following departments:  
- Clinical Trials  
- GCP inspections  
- Scientific advice  
- Legal affairs  
- Pharmacopoeia (also head of the German Pharmacopoeia)  
- Information technology
- June 2020- Present **Head of the Division "Information technology / clinical trials"**  
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (Germany)  
Division includes following departments:  
- Clinical Trials  
- Information technology including software development

#### EDUCATION AND TRAINING

---

- 1984- 1987 **Medical school / Study of Medicine**  
Rheinisch-Westfälische Technische Hochschule Aachen (Germany)
- 1984- 1987 **Medical school / Study of Medicine**  
Rheinische Friedrich-Wilhelms Universität Bonn (Germany)  
Medical Degree
- 1994- 1999 **Specialist in Clinical Pharmacology**  
Rheinische Friedrich-Wilhelms Universität Bonn - Institute for Clinical Pharmacology (Germany)  
Continuing medical education  
Board certified clinical pharmacologist

- 1994- **Doctoral Thesis**  
Rheinische Friedrich-Wilhelms Universität Bonn - Clinic for Epileptology (Germany)  
MD (Dr. med.)
- 2004- **Habilitation in Lipidology (venia legendi)**  
Rheinische Friedrich-Wilhelms Universität Bonn (Germany)

## ADDITIONAL INFORMATION

---

**Expertise** Clinical Medicine: Diabetes, lipidology  
Clinical Pharmacology  
Clinical Trials / GCP

- Publications**
- 1: Lauer W, Lobker W, Sudhop T, Broich K. Digitale Gesundheitsanwendungen (DiGA) als innovativer Baustein in der digitalen Gesundheitsversorgung in Deutschland - Informationen, Erfahrungen und Perspektiven [Digital health applications (DiGA) as an innovative component in digital healthcare in Germany-information, experiences, and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Oct;64(10):1195-1197. German. doi: 10.1007/s00103-021-03420-y. Epub 2021 Oct 5. PMID: 34609570; PMCID: PMC8492576.
  - 2: Sudhop T, Brun NC, Riedel C, Rosso A, Broich K, Senderovitz T. Master protocols in clinical trials: a universal Swiss Army knife? Lancet Oncol. 2019 Jun;20(6):e336-e342. doi: 10.1016/S1470-2045(19)30271-2. PMID: 31162107.
  - 3: Graf von Kielmansegg S, Benda N, Grass G, Sudhop T. Die Rolle von Ethikkommissionen bei der Bewertung klinischer Arzneimittelprüfungen [Ethics committees in clinical trials involving medicinal products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Jun;62(6):706-712. German. doi: 10.1007/s00103-019-02946-6. PMID: 31028415.
  - 4: Lauer W, Sudhop T, Broich K. E-Health und Medizinprodukte : Bundesgesundheitsblatt Schwerpunktheft [E-health and medical devices : Federal Health Gazette Special Issue]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Mar;61(3):249-251. German. doi: 10.1007/s00103-018-2714-2. PMID: 29468403.
  - 5: Fruhner K, Hartmann G, Sudhop T. Analysis of integrated clinical trial protocols in early phases of medicinal product development. Eur J Clin Pharmacol. 2017 Dec;73(12):1565-1577. doi: 10.1007/s00228-017-2335-y. Epub 2017 Sep 18. PMID: 28921395; PMCID: PMC5684304.
  - 6: Sudhop T, Krafft H. Klinische Prüfung von Arzneimitteln : Änderungen durch die kommende EU-Verordnung [Clinical Trials with Medicinal Products : Changes imposed by the new Clinical Trial Regulation]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Aug;60(8):793-794. German. doi: 10.1007/s00103-017-2587-9. PMID: 28748294.
  - 7: Sudhop T, Grass G, Wessler I. Gemeinsames Pilotprojekt von Bundesoberbehörden und Ethikkommissionen zur Umsetzung der EU-Verordnung zu klinischen Prüfungen [Joint pilot project of the German higher federal authorities and ethics committees on implementing the EU Regulation on clinical trials]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Aug;60(8):817-825. German. doi: 10.1007/s00103-017-2584-z. PMID: 28664274.
  - 8: Nickel L, Seibel Y, Frech M, Sudhop T. Änderungen des Arzneimittelgesetzes durch die EU-Verordnung zu klinischen Prüfungen [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Aug;60(8):804-811. German. doi: 10.1007/s00103-017-2574-1. PMID: 28664271.

- 9: Stellaard F, von Bergmann K, Sudhop T, Lutjohann D. The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies. *J Steroid Biochem Mol Biol.* 2017 May;169:111-122. doi: 10.1016/j.jsbmb.2016.03.030. Epub 2016 Apr 6. PMID: 27060336.
- 10: Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G. Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials. *Eur J Clin Pharmacol.* 2017 Apr;73(4):409-416. doi: 10.1007/s00228-016-2189-8. Epub 2017 Jan 7. PMID: 28064353; PMCID: PMC5350217.
- 11: Riedel C, Lehmann B, Broich K, Sudhop T. Arzneimittelzulassung für Kinder und Jugendliche verbessern : Positionspapier zum Kinderarzneimittel-Symposium am 8. Juni 2015 in Bonn [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposium 8 June 2015 in Bonn]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2016 Dec;59(12):1587-1592. German. doi: 10.1007/s00103-016-2459-8. PMID: 27778087.
- 12: Salmonson T, Janssen H, Sudhop T, Stahl E. Regulatory Reply to the ATMOSPHERE Data Monitoring Committee. *N Engl J Med.* 2016 Apr 21;374(16):1585-6. doi: 10.1056/NEJMc1603514. Epub 2016 Apr 4. PMID: 27043362.
- 13: Beinlich P, Müller-Berghaus J, Sudhop T, Vieths S, Broich K. Zusammenspiel zwischen Zulassung und Nutzenbewertung von Arzneimitteln [Interplay between marketing authorization and early benefit assessment of drugs]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2015 Mar;58(3):227-31. German. doi: 10.1007/s00103-014-2108-z. PMID: 25566840.
- 14: von Jeinsen BK, Sudhop T. A 1-year cross-sectional analysis of non-interventional post-marketing study protocols submitted to the German Federal Institute for Drugs and Medical Devices (BfArM). *Eur J Clin Pharmacol.* 2013 Jul;69(7):1453-66. doi: 10.1007/s00228-013-1482-z. Epub 2013 Mar 20. PMID: 23512215; PMCID: PMC3676740.
- 15: Berthold HK, Sudhop T, von Bergmann K, Gouni-Berthold I. Lifibrol as a model compound for a novel lipid-lowering mechanism of action. *J Cardiovasc Pharmacol Ther.* 2010 Dec;15(4):364-72. doi: 10.1177/1074248410371100. Epub 2010 Aug 6. PMID: 20693157.
- 16: Berthold HK, Mertens J, Birnbaum J, Bramswig S, Sudhop T, Barrett PH, von Bergmann K, Gouni-Berthold I. Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia. *Lipids.* 2010 Jun;45(6):491-500. doi: 10.1007/s11745-010-3420-5. Epub 2010 May 12. PMID: 20461472.
- 17: Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lutjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. *J Lipid Res.* 2009 Oct;50(10):2117-23. doi: 10.1194/jlr.P900004-JLR200. Epub 2009 Apr 20. PMID: 19380898; PMCID: PMC2739752.
- 18: Vogel M, Bertram N, Wasmuth JC, Wyen C, Voigt E, Schwarze-Zander C, Sudhop T, Fatkenheuer G, Rockstroh JK, Reichel C. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. *J Antimicrob Chemother.* 2009 May;63(5):988-91. doi: 10.1093/jac/dkp044. Epub 2009 Mar 6. PMID: 19270314.
- 19: Sudhop T. Besonderheiten bei der Anwendung nicht zugelassener Arzneimittel. Compassionate Use aus der Sicht der Bundesoberbehörden [Compassionate use of non-approved medicinal products. Legal basis and guidelines]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2009

Apr;52(4):439-43. German. doi: 10.1007/s00103-009-0829-1. PMID: 19343282.

20: Sudhop T, Enzmann H, Klar R. Klinische Forschung. Auswirkungen der europäischen Gesetzgebung und aktuelle Entwicklungen [Clinical research. Effects of European legislation and current developments]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Apr;52(4):375-6. German. doi: 10.1007/s00103-009-0845-1. PMID: 19343281.

21: Weingartner O, Lutjohann D, Ji S, Weisshoff N, List F, Sudhop T, von Bergmann K, Gertz K, König J, Schafers HJ, Endres M, Böhm M, Laufs U. Vascular effects of diet supplementation with plant sterols. *J Am Coll Cardiol*. 2008 Apr 22;51(16):1553-61. doi: 10.1016/j.jacc.2007.09.074. PMID: 18420097.

22: Knabe C, Sudhop T, von Bergmann K, Lutjohann D. Degradation of 24S-hydroxycholesterol in men is not regulated by CYP7A1. *Int J Clin Pharmacol Ther*. 2007 Nov;45(11):577-82. doi: 10.5414/cpp45577. PMID: 18077921.

23: Clarenbach JJ, Reber M, Lutjohann D, von Bergmann K, Sudhop T. The lipid-lowering effect of ezetimibe in pure vegetarians. *J Lipid Res*. 2006 Dec;47(12):2820-4. doi: 10.1194/jlr.P600009-JLR200. Epub 2006 Sep 11. PMID: 16966491.

24: Gerloff T, Schaefer M, Mwinyi J, John A, Sudhop T, Lutjohann D, Roots I, von Bergmann K. Influence of the SLCO1B1\*1b and \*5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. *Naunyn Schmiedebergs Arch Pharmacol*. 2006 Apr;373(1):45-50. doi: 10.1007/s00210-006-0053-6. Epub 2006 Mar 28. PMID: 16568260.

25: Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. *Clin Pharmacol Ther*. 2006 Mar;79(3):206-17. doi: 10.1016/j.cpt.2005.11.004. Epub 2006 Feb 7. PMID: 16513445.

26: Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. *J Lipid Res*. 2005 Dec;46(12):2692-8. doi: 10.1194/jlr.M500260-JLR200. Epub 2005 Sep 14. PMID: 16162943.

27: von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and plant sterol absorption: recent insights. *Am J Cardiol*. 2005 Jul 4;96(1A):10D-14D. doi: 10.1016/j.amjcard.2005.03.014. PMID: 15992510.

28: Thuluva SC, Igel M, Giesa U, Lutjohann D, Sudhop T, von Bergmann K. Ratio of lathosterol to campesterol in serum predicts the cholesterol-lowering effect of sitostanol-supplemented margarine. *Int J Clin Pharmacol Ther*. 2005 Jul;43(7):305-10. doi: 10.5414/cpp43305. PMID: 16035372.

29: Sudhop T, Lutjohann D, von Bergmann K. Sterol transporters: targets of natural sterols and new lipid lowering drugs. *Pharmacol Ther*. 2005 Mar;105(3):333-41. doi: 10.1016/j.pharmthera.2004.10.011. Epub 2004 Dec 9. PMID: 15737409.

30: Sudhop T, von Bergmann K. Sitosterolemia--a rare disease. Are elevated plant sterols an additional risk factor? *Z Kardiol*. 2004 Dec;93(12):921-8. doi: 10.1007/s00392-004-0165-2. PMID: 15599566.

31: Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, Sauerbruch T, Rockstroh JK, Spengler U. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-

- transplanted HIV-infected patients. *Liver Transpl.* 2004 Jul;10(7):939-44. doi: 10.1002/lt.20165. PMID: 15237382.
- 32: Lutjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K, Reichel C. Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. *Int J Clin Pharmacol Ther.* 2004 Jun;42(6):307-13. doi: 10.5414/cpp42307. PMID: 15222722.
- 33: Weinbrenner T, Zuger M, Jacoby GE, Herpertz S, Liedtke R, Sudhop T, Gouni-Berthold I, Axelson M, Berthold HK. Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. *Br J Nutr.* 2004 Jun;91(6):959-69. doi: 10.1079/BJN20041151. PMID: 15182399.
- 34: Igel-Korcagova A, Raab P, Brensing KA, Poge U, Klehr HU, Igel M, von Bergmann K, Sudhop T. Cholesterol metabolism in patients with chronic renal failure on hemodialysis. *J Nephrol.* 2003 Nov-Dec;16(6):850-4. PMID: 14736012.
- 35: Sudhop T, von Bergmann K. KHK-Pravention: Wichtig ist doch nur die Entzündungshemmung. Wozu dann noch Lipide senken? [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. *MMW Fortschr Med.* 2003 May 22;145(21):19. German. PMID: 12845862.
- 36: Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. *Am J Gastroenterol.* 2003 May;98(5):1167-74. doi: 10.1111/j.1572-0241.2003.07515.x. PMID: 12809844.
- 37: Sudhop T, von Bergmann K. Ezetimib als Kombinationspartner bei Hypercholesterinämie. LDL-Senkung über die Statinwirkung hinaus [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins]. *MMW Fortschr Med.* 2003 Apr 17;145(16):48-50. German. PMID: 14606402.
- 38: Bramswig S, Sudhop T, Luers C, von Bergmann K, Berthold HK. Lipoprotein(a) concentration increases during treatment with carbamazepine. *Epilepsia.* 2003 Mar;44(3):457-60. doi: 10.1046/j.1528-1157.2003.44802.x. PMID: 12614404.
- 39: Sudhop T, von Bergmann K. Clinical trials, industrial sponsoring, and ethics --a never ending story? *Int J Clin Pharmacol Ther.* 2003 Feb;41(2):49-50. doi: 10.5414/cpp41049. PMID: 12607626.
- 40: Sudhop T, Lutjohann D, Agna M, von Ameln C, Prange W, von Bergmann K. Comparison of the effects of sitostanol, sitostanol acetate, and sitostanol oleate on the inhibition of cholesterol absorption in normolipemic healthy male volunteers. A placebo controlled randomized cross-over study. *Arzneimittelforschung.* 2003;53(10):708-13. doi: 10.1055/s-0031-1299816. PMID: 14650363.
- 41: Igel M, Sudhop T, von Bergmann K. Pleiotrophe Effekte von Statinen (3-Hydroxy-3-Methylglutaryl-Coenzym A-Reduktasehemmer) [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)]. *Arzneimittelforschung.* 2003;53(8):545-53. German. doi: 10.1055/s-0031-1297148. PMID: 13677244.
- 42: Wasmuth JC, Schliefer K, Scheurlen C, Sudhop T, Rockstroh JK, Sauerbruch T, Spengler U. Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infection. *Eur J Med Res.* 2002 Dec 17;7(12):536-42. PMID: 12527499.
- 43: Sudhop T, Gottwald BM, von Bergmann K. Serum plant sterols as a potential risk factor for coronary heart disease. *Metabolism.* 2002 Dec;51(12):1519-21. doi: 10.1053/meta.2002.36298. PMID: 12489060.
- 44: Sudhop T, Sahin Y, Lindenthal B, Hahn C, Luers C, Berthold HK, von Bergmann

K. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. *Gut*. 2002 Dec;51(6):860-3. doi: 10.1136/gut.51.6.860. PMID: 12427790; PMCID: PMC1773453.

45: Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation*. 2002 Oct 8;106(15):1943-8. doi: 10.1161/01.cir.0000034044.95911.dc. PMID: 12370217.

46: Schafer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. *Chest*. 2002 Sep;122(3):829-39. doi: 10.1378/chest.122.3.829. PMID: 12226021.

47: Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. *J Clin Pharmacol*. 2002 Aug;42(8):835-45. doi: 10.1177/009127002401102731. Erratum in: *J Clin Pharmacol*. 2003 Sep;43(9):1015. PMID: 12162466.

48: Brensing KA, Raab P, Textor J, Gorich J, Schiedermaier P, Strunk H, Paar D, Schepke M, Sudhop T, Spengler U, Schild H, Sauerbruch T. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. *Eur J Gastroenterol Hepatol*. 2002 Jul;14(7):723-31. doi: 10.1097/00042737-200207000-00003. PMID: 12169980.

49: Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. *J Lipid Res*. 2002 Jul;43(7):1072-7. doi: 10.1194/jlr.m100438-jlr200. PMID: 12091491.

50: Lindenthal B, Aldaghas TA, Holleran AL, Sudhop T, Berthold HK, Von Bergmann K, Kelleher JK. Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells. *Am J Physiol Endocrinol Metab*. 2002 Jun;282(6):E1222-30. doi: 10.1152/ajpendo.00324.2001. PMID: 12006351.

51: Bramswig S, Kerksiek A, Sudhop T, Luers C, Von Bergmann K, Berthold HK. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. *Am J Physiol Heart Circ Physiol*. 2002 Feb;282(2):H704-16. doi: 10.1152/ajpheart.00580.2001. PMID: 11788421.

52: Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. *Drugs*. 2002;62(16):2333-47. doi: 10.2165/00003495-200262160-00002. PMID: 12396226.

53: Zittermann A, Ruhl J, Berthold HK, Sudhop T, van der Ven H, Reinsberg J, Stehle P. Oral contraceptives moderately effect bone resorption markers and serum-soluble interleukin-6 receptor concentrations. *Calcif Tissue Int*. 2002 Jan;70(1):11-21. doi: 10.1007/s002230020035. Epub 2001 Dec 21. PMID: 11907703.

54: Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). *Eur J Clin Pharmacol*. 2001 Aug;57(5):357-64. doi: 10.1007/s002280100329. PMID: 11599653.

55: von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. *J Hypertens Suppl*. 2001 Jun;19(1):S33-40. doi: 10.1097/00004872-200106001-00005. PMID: 11451213.

56: Reichel C, Sudhop T, Braun B, Kreuzer KA, Hahn C, Look MP, von Bergmann K, Sauerbruch T, Spengler U. Elevated soluble tumour necrosis factor receptor serum concentrations and short-term mortality in liver cirrhosis without acute

infections. *Digestion*. 2000;62(1):44-51. doi: 10.1159/00007777. PMID: 10899725.

57: Zittermann A, Schwarz I, Scheld K, Sudhop T, Berthold HK, von Bergmann K, van der Ven H, Stehle P. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. *J Clin Endocrinol Metab*. 2000 Jan;85(1):95-101. doi: 10.1210/jcem.85.1.6250. PMID: 10634371.

58: Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U. Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. *Antiviral Res*. 1999 Sep;43(2):113-22. doi: 10.1016/s0166-3542(99)00041-8. PMID: 10517313.

59: Sudhop T, Bauer J, Elger CE, von Bergmann K. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. *Epilepsia*. 1999 Apr;40(4):480-4. doi: 10.1111/j.1528-1157.1999.tb00744.x. PMID: 10219275.

60: Luers C, Sudhop T, Spengler U, Berthold HK. Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection. *J Hepatol*. 1999 Feb;30(2):347. doi: 10.1016/s0168-8278(99)80085-3. PMID: 10068119.

61: Berthold HK, Sudhop T. Garlic preparations for prevention of atherosclerosis. *Curr Opin Lipidol*. 1998 Dec;9(6):565-9. doi: 10.1097/00041433-199812000-00008. PMID: 9868592.

62: Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. *JAMA*. 1998 Jun 17;279(23):1900-2. doi: 10.1001/jama.279.23.1900. PMID: 9634262.

63: Rockstroh JK, Woitas RP, Brackmann HH, Kupfer B, Kaiser R, Schneeweis KE, Sudhop T, Spengler U. In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count. *Eur J Med Res*. 1998 May 12;3(5):223-30. PMID: 9580568.

64: Look MP, Rockstroh JK, Rao GS, Barton S, Lemoch H, Kaiser R, Kupfer B, Sudhop T, Spengler U, Sauerbruch T. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. *Eur J Clin Invest*. 1998 May;28(5):389-97. doi: 10.1046/j.1365-2362.1998.00301.x. PMID: 9650013.

65: Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY. How do clinicians practicing in the U.S. manage *Helicobacter pylori*-related gastrointestinal diseases? A comparison of primary care and specialist physicians. *Am J Gastroenterol*. 1998 Apr;93(4):553-61. doi: 10.1111/j.1572-0241.1998.164\_b.x. PMID: 9576447.

66: Breuer T, Sudhop T, Goodman KJ, Graham DY, Malfertheiner P. How do practicing clinicians manage *Helicobacter pylori*-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. *Helicobacter*. 1998 Mar;3(1):1-8. doi: 10.1046/j.1523-5378.1998.08027.x. PMID: 9546111.

67: Reichel C, Nacke A, Sudhop T, Wienkoop G, Luers C, Hahn C, Pohl C, Spengler U, Sauerbruch T. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. *Hepatology*. 1997 Jun;25(6):1323-7. doi: 10.1002/hep.510250603. PMID: 9185746.

68: Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Barton S, Lemoch H, Sudhop T, Hoch J, Stockinger K, Spengler U, Sauerbruch T. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. *Eur J Clin Nutr*. 1997 Apr;51(4):266-72. doi: 10.1038/sj.ejcn.1600401. PMID: 9104578.

- 69: Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfecting with HIV. *Am J Gastroenterol.* 1996 Dec;91(12):2563-8. PMID: 8946987.
- 70: Breuer T, Sudhop T, Hoch J, Sauerbruch T, Malferteiner P. Prevalence of and risk factors for *Helicobacter pylori* infection in the western part of Germany. *Eur J Gastroenterol Hepatol.* 1996 Jan;8(1):47-52. doi: 10.1097/00042737-199601000-00009. PMID: 8900908.
- 71: Sudhop T, Lutjohann D, Ratman C, von Bergmann J, von Bergmann K. Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia. *Eur J Clin Pharmacol.* 1996;50(5):365-9. doi: 10.1007/s002280050124. PMID: 8839657.
- 72: Grunwald F, Spath G, Menzel C, Pavics L, Sudhop T, Liesegang P, Klingmuller D, Schomburg A, Biersack HJ. Nebenschilddrusenzintigraphie mit 99mTc-MIBI [Scintigraphy of the parathyroid glands with 99mTc-MIBI]. *Med Klin (Munich).* 1995 Aug 15;90(8):450-5. German. PMID: 7565402.
- 73: Reichel C, Wienkoop G, Nacke A, Sudhop T, Spengler U, Sauerbruch T. Which lidocaine dose should be used for the MEGX liver function test? *J Hepatol.* 1995 May;22(5):600. doi: 10.1016/0168-8278(95)80462-5. PMID: 7650345.
- 74: Hufnagel A, Claus D, Brunhoelzl C, Sudhop T. Short-term memory: no evidence of effect of rapid-repetitive transcranial magnetic stimulation in healthy individuals. *J Neurol.* 1993 Jun;240(6):373-6. doi: 10.1007/BF00839970. PMID: 8336179.

#### Book chapters:

- Sudhop T und von Bergmann K. Pharmaka zur Therapie von Stoffwechselkrankheiten. In: Estler C und Schmidt H (eds.). *Pharmakologie und Toxikologie. Lehrbuch für Studium und Praxis.* Stuttgart, 2006: 759-784
- Sudhop T, Neubrand M, Berthold HK. Gastroenterologische Erkrankungen. In: Berthold HK (eds.). *Klinikleitfaden Arzneimitteltherapie.* München, Jena: Urban und Fischer, 2003 (2nd edition):365-475.
- Berthold HK, Sudhop T. Therapie mit Analgetika. In: Berthold HK (ed.). *Klinikleitfaden Arzneimitteltherapie.* München, Jena: Urban und Fischer, 2003 (2nd edition):865-904.
- Berthold HK, Sudhop T. Entwicklung und Anwendung von Arzneimitteln. In: Berthold HK (ed.). *Klinikleitfaden Arzneimitteltherapie.* München, Jena: Urban und Fischer, 2003 (2nd edition):1-72.
- Sudhop T, von Bergmann K. Ethische Grundlagen für Klinische Prüfungen am Menschen. In: Herrlinger C und Cawello W (eds.). *Kompodium der Klinischen Pharmakologie.* Aachen: Shaker 2002: 43-56
- von Bergmann K, Sudhop T. Arzneimittel zur Behandlung der Gicht. In: Estler C (ed.). *Pharmakologie und Toxikologie. Lehrbuch für Studierende der Medizin, Pharmazie und Naturwissenschaften.* Stuttgart: Schattauer, 2000 (5th edition):587-591.
- Sudhop T, von Bergmann K. Arzneimittel zur Behandlung von Fettstoffwechselstörungen. In: Estler C (ed.). *Pharmakologie und Toxikologie. Lehrbuch für Studierende der Medizin, Pharmazie und Naturwissenschaften.* Stuttgart: Schattauer, 2000 (5th edition):572-586.

#### Projects

- Doctoral Thesis:[A computerised EEG-coupled neuropsychometric test system] 1994, Medical Faculty of the University of Bonn
- Habilitation: [The importance of plant sterols in human lipid metabolism and their pharmacological influence.] 2003, Medical Faculty of the University of Bonn
- Former Deputy Head and Member of the Examination Board of the Postgraduate Master's course in Drug Regulatory Affairs of the Faculty of Mathematics and Natural Sciences of the University of Bonn
- Various lectures in human medicine, pharmacology and drug regulatory affairs at the University of Bonn

#### Memberships

- Examination Board of the Postgraduate Master's course in Drug Regulatory Affairs of the Faculty of Mathematics and Natural Sciences of the University of Bonn
- Association for Applied Human Pharmacology (AGAH)
- Professional Association of German Internists e.V.



Former Memberships

Ethics committee of the Medical Association North Rhine (1999 - 2004)

Other Relevant Information